Agilent Technologies Target Oral Cancer with New Collaboration
Agilent Technologies (California, USA) is to collaborate with the University of Queensland Centre for Clinical Research (Brisbane, Australia) to further understanding of the genomic differences governing oral cancer. According to the National Center for Biotechnology Information, oral cancer is the sixth most prevalent cancer worldwide.
Agilent Technologies (California, USA) is to collaborate with the University of Queensland Centre for Clinical Research (Brisbane, Australia) to further understanding of the genomic differences governing oral cancer. According to the National Center for Biotechnology Information, oral cancer is the sixth most prevalent cancer worldwide.
Oral potentially malignant lesions (OPMLs) are visibly altered precursors of many oral squamous cell carcinomas (OSCCs), but the reason for the transition is not known. The researchers involved hope to implement next-generation sequencing and data analysis to identify the molecular basis of the transition and therefore open up new targets for therapeutic drugs. Camile Farah, Head of the Oral Oncology Research Programme, said: "Our collaboration and support from Agilent will accelerate our work in this important area of clinical research."
For more information visit: www.uqccr.uq.edu.au
Influence of Concentration in Conventional GPC/SEC and Advanced Detection GPC/SEC
March 21st 2025Sample concentration is a parameter that can influence the quality of gel permeation chromatography/size-exclusion chromatography (GPC/SEC) separations and the obtained results. Understanding this influence can help to support the development of reliable GPC/SEC methods.
Multi-Step Preparative LC–MS Workflow for Peptide Purification
March 21st 2025This article introduces a multi-step preparative purification workflow for synthetic peptides using liquid chromatography–mass spectrometry (LC–MS). The process involves optimizing separation conditions, scaling-up, fractionating, and confirming purity and recovery, using a single LC–MS system. High purity and recovery rates for synthetic peptides such as parathormone (PTH) are achieved. The method allows efficient purification and accurate confirmation of peptide synthesis and is suitable for handling complex preparative purification tasks.
